Snehal International Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit 2031.81%
(FY 2022)
- Ebitda 2675.42%
(FY 2022)
- Net Worth 334.74%
(FY 2022)
- Total Assets 464.32%
(FY 2022)
About Snehal International Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sudhir Deulgaonkar and Mrudula Deulgaonkar serve as directors at the Company.
- CIN/LLPIN
U24290MH2020PTC345294
- Company No.
345294
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Sep 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Snehal International Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhir Deulgaonkar  | Director | 04-Sep-2020 | Current |
| Mrudula Deulgaonkar | Director | 04-Sep-2020 | Current |
Financial Performance of Snehal International Pharma.
Snehal International Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 2031.81% increase in profit. The company's net worth Soared by an impressive increase of 334.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Snehal International Pharma?
Unlock access to Snehal International Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Snehal Pharma & Surgicals Private LimitedActive 13 years 6 monthsSudhir Deulgaonkar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Snehal International Pharma?
Snehal International Pharma has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Snehal International Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Snehal International Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
